Trialing precision medicine for type 2 diabetes

Scott J Pilla^{1

2

3}, Nestoras N Mathioudakis⁴, Nisa M Maruthur^{5

6

7}

Affiliations

¹ Department of Medicine, Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.
³ Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
⁴ Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁵ Department of Medicine, Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. maruthur@jhmi.edu.
⁶ Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. maruthur@jhmi.edu.
⁷ Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. maruthur@jhmi.edu.

Comment

Scott J Pilla et al. Nat Med. 2023 Feb.

. 2023 Feb;29(2):309-310.

doi: 10.1038/s41591-022-02168-5.

Scott J Pilla^{1

2

3}, Nestoras N Mathioudakis⁴, Nisa M Maruthur^{5

6

7}

¹ Department of Medicine, Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.
³ Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
⁴ Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁵ Department of Medicine, Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. maruthur@jhmi.edu.
⁶ Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. maruthur@jhmi.edu.
⁷ Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. maruthur@jhmi.edu.

No abstract available

Comment on

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.
Shields BM, Dennis JM, Angwin CD, Warren F, Henley WE, Farmer AJ, Sattar N, Holman RR, Jones AG, Pearson ER, Hattersley AT; TriMaster Study group. Shields BM, et al. Nat Med. 2023 Feb;29(2):376-383. doi: 10.1038/s41591-022-02120-7. Epub 2022 Dec 7. Nat Med. 2023. PMID: 36477733 Free PMC article. Clinical Trial.
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
Shields BM, Angwin CD, Shepherd MH, Britten N, Jones AG, Sattar N, Holman R, Pearson ER, Hattersley AT. Shields BM, et al. Nat Med. 2023 Feb;29(2):384-391. doi: 10.1038/s41591-022-02121-6. Epub 2022 Dec 7. Nat Med. 2023. PMID: 36477734 Free PMC article. Clinical Trial.

1. Philipson, L. H. Nat. Rev. Endocrinol. 16, 79–80 (2020). - DOI - PubMed - PMC
1. Davies, M. J. et al. Diabetes Care 45, 2753–2786 (2022). - DOI - PubMed
1. Shields, B. M. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02120-7 (2022). - DOI - PubMed
1. Shields, B. M. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02121-6 (2022). - DOI - PubMed
1. Brankovic, M. et al. Eur. J. Clin. Invest. 49, e13145 (2019). - DOI - PubMed